Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

Vivus, Inc. Announces Resignation of Allan L. Shaw from its Audit Committee and Compensation Committee

March 03, 2018 at 02:36 am IST

On February 26, 2018, VIVUS, Inc. and Allan L. Shaw entered into a Consulting Agreement, effective February 1, 2018. Effective February 1, 2018, Mr. Shaw resigned from the Company’s Audit Committee and Compensation Committee. Mr. Shaw has served as a member of the company’s Board of Directors, since September 15, 2015, and Mr. Shaw will continue serving on the Board.

Latest news about VIVUS, Inc.

Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	30/05	CI
VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	22/04	CI
VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	28/11	CI
VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	10/23/10	CI
FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	20/22/20	CI
VIVUS, Inc. Emerged from Bankruptcy	11/20/11	CI
Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	10/20/10	CI
First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	17/20/17	CI
Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	10/20/10	CI
First Motion for Exclusivity Period Extension Filed by VIVUS, Inc.	04/20/04	CI
Motion for Asset Sale Filed by VIVUS, Inc.	20/20/20	CI
First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	18/20/18	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from S&P TMI Index	10/20/10	CI
Motion for Joint Administration Approved for VIVUS, Inc.	10/20/10	CI
Combined Hearing for Disclosure Statement and Plan Approved for VIVUS, Inc.	10/20/10	CI
Health Care Flat As Growth Investors Seek Out Tech -- Health Care Roundup	09/20/09	DJ
VIVUS, Inc. Appoints Jill Frizzley as a Independent Director of the Company	08/20/08	CI
VIVUS, Inc. Filed for Bankruptcy	07/20/07	CI
Motion for Joint Administration Filed by VIVUS, Inc.	07/20/07	CI
Joint Pre-Packaged Reorganization Plan and Disclosure Statement Filed by VIVUS, Inc.	07/20/07	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Index	26/20/26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Value Index	26/20/26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Growth Index	26/20/26	CI
VIVUS, Inc. Contemplates Bankruptcy	02/20/02	CI
Transcript : VIVUS, Inc., Q1 2020 Earnings Call, May 06, 2020	07/20/07

Chart VIVUS, Inc.

Duration

Period

More charts

Company Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+56.86%	82TCr
NOVO NORDISK A/S	+43.90%	64TCr
JOHNSON & JOHNSON	-6.57%	35TCr
MERCK & CO., INC.	+17.32%	31TCr
ABBVIE INC.	+9.94%	30TCr
ASTRAZENECA PLC	+16.08%	24TCr
ROCHE HOLDING AG	+2.29%	22TCr
NOVARTIS AG	+13.96%	22TCr
AMGEN INC.	+7.98%	17TCr

Other Pharmaceuticals